Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222529

Enrollment

Registered

2014-06-18

Start date

2014-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B cell Non-Hodgkin s Lymphoma

Interventions

investigational material(s) Generic name etc : RO5541077 INN of investigational material : polatuzumab vedotin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Inve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status (PS) of 0 or 1 Relapsed or refractory B cell NHL for which there is no prior standard treatment Sufficient major organ function

Exclusion criteria

Exclusion criteria: Pregnant or lactating women or women who have tested positive on a pregnancy test Current or previous history of clinically significant disease Current or previous history of central nervous system lymphoma Invasion to the CNS of the primary disease

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics Assessment and observations	—

Secondary

Measure	Time frame
safety efficacy Assessment and observation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026